Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib

被引：6
|
作者：
Piper-Vallillo, Andrew J. [1 ,2 ,3 ]
Sequist, Lecia V. [2 ,3 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] Massachusetts Gen Hosp, 55 Fruit St,BHX-1-125, Boston, MA 02114 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
来源：
JACC: CARDIOONCOLOGY | 2019年 / 1卷 / 02期
关键词：
cardiotoxicity; EGFR; NSCLC; osimertinib;
D O I：
10.1016/j.jaccao.2019.11.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：179 / 181
页数：3
相关论文
共 50 条
  • [31] Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer
    Choi, Mihong
    Keam, Bhumsuk
    Ock, Chan-Young
    Kim, Miso
    Kim, Tae Min
    Kim, Dong-Wan
    Heo, Dae Seog
    CLINICAL LUNG CANCER, 2019, 20 (04) : E442 - E451
  • [32] Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment
    Del Re, Marzia
    Addeo, Alfredo
    Passaro, Antonio
    Petrini, Iacopo
    van Schaik, Ron H. N.
    Danesi, Romano
    PHARMACOGENOMICS, 2019, 20 (18) : 1255 - 1257
  • [33] Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives
    Ricciuti, Biagio
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S249 - S252
  • [34] Osimertinib early dose reduction as a risk to brain metastasis control in EGFR-mutant non-small cell lung cancer
    Tozuka, Takehiro
    Noro, Rintaro
    Miyanaga, Akihiko
    Nakamichi, Shinji
    Takeuchi, Susumu
    Matsumoto, Masaru
    Kubota, Kaoru
    Kasahara, Kazuo
    Seike, Masahiro
    CANCER MEDICINE, 2023, 12 (17): : 17731 - 17739
  • [35] A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers.
    Yu, Helena Alexandra
    Hayes, Sara A.
    Young, Robert J.
    Ni, Ai
    Rodriguez, Christopher
    Makhnin, Alex
    Riely, Gregory J.
    Kris, Mark G.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers
    Qi, Chuang
    Cui, Huanxi
    Chen, Dongsheng
    JAMA ONCOLOGY, 2020, 6 (12)
  • [37] Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
    Gen, Soei
    Tanaka, Ichidai
    Morise, Masahiro
    Koyama, Junji
    Kodama, Yuta
    Matsui, Akira
    Miyazawa, Ayako
    Hase, Tetsunari
    Hibino, Yoshitaka
    Yokoyama, Toshihiko
    Kimura, Tomoki
    Yoshida, Norio
    Sato, Mitsuo
    Hashimoto, Naozumi
    BMC CANCER, 2022, 22 (01)
  • [38] Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
    Soei Gen
    Ichidai Tanaka
    Masahiro Morise
    Junji Koyama
    Yuta Kodama
    Akira Matsui
    Ayako Miyazawa
    Tetsunari Hase
    Yoshitaka Hibino
    Toshihiko Yokoyama
    Tomoki Kimura
    Norio Yoshida
    Mitsuo Sato
    Naozumi Hashimoto
    BMC Cancer, 22
  • [39] Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer
    Cao, Fei
    Gong, Ya-Bin
    Kang, Xiao-Hong
    Lu, Zhi-Hong
    Wang, Ying
    Zhao, Ke-Lei
    Miao, Zhan-Hui
    Liao, Ming-Juan
    Xu, Zhen-Ye
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2019, 379
  • [40] A Phase 2 Trial Assessing Osimertinib Activity Against Leptomeningeal Carcinomatosis in EGFR-Mutant Lung Cancer
    Akazawa, Y.
    Nanjo, S.
    Tamiya, M.
    Hata, A.
    Yamaguchi, T.
    Kumagai, T.
    Mori, M.
    Katakami, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S918 - S918
12345